Investing.com -- AstraZeneca PLC Azn is the strongest all-round European big pharma candidate 22.
AstraZeneca PLC (AZN) โ Live Session & Technical Brief
Updated Nov 21, 2026 5:53 PM ET ยท Prev Close $175.41
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (-0.60%) in Drug Manufacturers - General
AstraZeneca PLC (Azn) is trading within a tight intraday band at $174.35 (-0.60%, 0.71x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, AZN is outperforming the S&P 500 by +3.04%. 14-day RSI stands at 44.4, keeping momentum in a bearish regime.
Investing.com -- AstraZeneca PLC Azn is the strongest all-round European big pharma candidate 22.
Price ($174.35) trades relative to 20-day SMA ($181.54) and 50-day SMA ($170.71).
Market & Sector Relative Strength
AZN outperforming the S&P 500 by +3.04%Recent AZN Catalyst Headlines
Verified WireAstraZeneca gains FDA priority review for its Sone-Ve cancer drug application, with a regulatory decision expected in Q2 2027.
Dublin, Nov. 20, 2026 Globe Newswire -- Oncology Clinical Trials - Global Strategic Business Report 2026 has been added to ResearchAndMarkets.com's offering. The global oncology clinical trials market was valued at US 11
Owning AstraZeneca directly means your results lean heavily on what happens to that single business. Simply Wall St highlights that the group has a high level of debt, and that late stage research such as the large trans
1โ3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $181.54 (20-day SMA resistance) for directional breakout confirmation.
Technical Regime (AZN)
MIXED MA TRENDRetail & Crowd Sentiment
NeutralAbout AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from โฆ
Get Instant AZN Catalyst Alerts
Receive an email alert when AZN triggers an unusual volume breakout, options sweep, or rating shift.
AZN Session & Catalyst FAQ
Why is AZN stock trading near flat today?
AstraZeneca PLC (Azn) is trading within a tight intraday band at $174.35 (-0.60%, 0.71x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, AZN is outperforming the S&P 500 by +3.04%. 14-day RSI stands at 44.4, keeping momentum in a bearish regime.
Is AZN stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.71x relative volume (low participation). Our multi-factor model currently rates AZN as AVOID NEW MONEY. Review full valuation, quality, and timing signals on the AZN Buy or Sell Decision Brief โ
What is AZN's intrinsic value and expected trading range?
At $174.35, AZN's modeled 1-to-3 session range is $169.80 โ $178.90, with a key inflection level at $181.54 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the AZN Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for AZN?
RSI at 44.4 reflects soft below-midline momentum. AZN trades at $174.35 relative to its 20-day SMA ($181.54) and 50-day SMA ($170.71), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.